Facioscapulohumeral Muscular Dystrophy
Avidity Biosciences Inc. funds clinical research in facioscapulohumeral muscular dystrophy, with studies centered on muscle function, mobility, and disease-related weakness in affected adults.
- Functional mobility
- Muscle strength
- Neuromuscular disease
Its clinical activity in this area reflects a focus on therapies for inherited muscle disorders that affect movement and daily physical performance.
Myotonic Dystrophy Type 1
The sponsor also supports research in myotonic dystrophy type 1, with attention to hand function, long-term tolerability, and the broader burden of this multisystem neuromuscular disorder.
- Hand function
- Long-term safety
- Inherited muscle disease
This area of interest includes clinical evaluation of treatments intended for chronic motor impairment associated with DM1.
Muscle Disease Therapeutics
Avidity Biosciences Inc. is active in therapeutic development for rare muscle diseases, particularly conditions that involve progressive weakness and reduced limb or hand performance.
- Rare disease treatment
- Progressive muscle weakness
- Motor impairment
The funded studies emphasize clinical endpoints tied to physical function in inherited muscular dystrophy populations.
Neuromuscular Clinical Development
The sponsor’s trial portfolio is concentrated in neuromuscular medicine, covering patient groups with genetic muscle disorders across multiple active study sites and countries.
- Genetic neuromuscular disorders
- Adult neurology
- Multinational clinical research
Its research landscape is defined by ongoing clinical evaluation in disorders where muscle performance and daily function are central therapeutic concerns.
